Mini review: Current status and perspective of S100B protein as a biomarker in daily clinical practice for diagnosis and prognosticating of clinical outcome in patients with neurological diseases with focus on acute brain injury

BMC Neurosci. 2023 Jul 20;24(1):38. doi: 10.1186/s12868-023-00807-2.

Abstract

Prognosticating the clinical outcome of neurological diseases is essential to guide treatment and facilitate decision-making. It usually depends on clinical and radiological findings. Biomarkers have been suggested to support this process, as they are deemed objective measures and can express the extent of tissue damage or reflect the degree of inflammation. Some of them are specific, and some are not. Few of them, however, reached the stage of daily application in clinical practice. This mini review covers available applications of the S100B protein in prognosticating clinical outcome in patients with various neurological disorders, particularly in those with traumatic brain injury, spontaneous subarachnoid hemorrhage and ischemic stroke. The aim is to provide an understandable picture of the clinical use of the S100B protein and give a brief overview of the current limitations that require future solutions.

Keywords: S100B; Subarachnoid hemorrhage; Traumatic brain injury.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Brain Injuries* / diagnosis
  • Humans
  • Nervous System Diseases* / diagnosis
  • Prognosis
  • S100 Calcium Binding Protein beta Subunit / metabolism

Substances

  • Biomarkers
  • S100 Calcium Binding Protein beta Subunit
  • S100B protein, human